Ajanta Pharma Past Earnings Performance
Past criteria checks 6/6
Ajanta Pharma has been growing earnings at an average annual rate of 10.6%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 12.6% per year. Ajanta Pharma's return on equity is 23.8%, and it has net margins of 19.5%.
Key information
10.6%
Earnings growth rate
11.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 12.6% |
| Return on equity | 23.8% |
| Net Margin | 19.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Dec 15
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Revenue & Expenses Breakdown
How Ajanta Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 44,908 | 8,750 | 10,215 | 0 |
| 30 Jun 24 | 43,326 | 8,538 | 9,828 | 0 |
| 31 Mar 24 | 42,087 | 8,162 | 9,122 | 0 |
| 31 Dec 23 | 40,365 | 7,357 | 9,031 | 0 |
| 30 Sep 23 | 39,031 | 6,602 | 8,642 | 0 |
| 30 Jun 23 | 38,128 | 6,215 | 8,280 | 0 |
| 31 Mar 23 | 37,426 | 5,880 | 7,978 | 0 |
| 31 Dec 22 | 37,311 | 6,169 | 7,383 | 0 |
| 30 Sep 22 | 35,972 | 6,742 | 7,081 | 0 |
| 30 Jun 22 | 35,439 | 7,136 | 6,821 | 0 |
| 31 Mar 22 | 33,410 | 7,127 | 6,571 | 0 |
| 31 Dec 21 | 32,275 | 7,207 | 6,301 | 0 |
| 30 Sep 21 | 31,384 | 7,056 | 6,041 | 0 |
| 30 Jun 21 | 29,695 | 6,799 | 5,745 | 0 |
| 31 Mar 21 | 28,897 | 6,539 | 5,523 | 0 |
| 31 Dec 20 | 28,148 | 6,238 | 5,354 | 0 |
| 30 Sep 20 | 27,173 | 5,547 | 5,196 | 0 |
| 30 Jun 20 | 26,441 | 5,008 | 5,065 | 0 |
| 31 Mar 20 | 25,879 | 4,677 | 4,890 | 0 |
| 31 Dec 19 | 24,211 | 4,274 | 4,831 | 0 |
| 30 Sep 19 | 22,550 | 3,868 | 4,755 | 0 |
| 30 Jun 19 | 21,563 | 3,958 | 4,639 | 0 |
| 31 Mar 19 | 20,554 | 3,870 | 4,503 | 0 |
| 31 Dec 18 | 20,654 | 3,926 | 4,428 | 0 |
| 30 Sep 18 | 21,674 | 4,731 | 4,252 | 0 |
| 30 Jun 18 | 21,636 | 4,796 | 4,089 | 0 |
| 31 Mar 18 | 21,258 | 4,686 | 3,908 | 0 |
| 31 Dec 17 | 20,590 | 4,882 | 3,574 | 0 |
| 30 Sep 17 | 20,050 | 4,833 | 3,397 | 0 |
| 30 Jun 17 | 19,805 | 4,821 | 3,224 | 0 |
| 31 Mar 17 | 19,833 | 5,068 | 3,060 | 0 |
| 31 Dec 16 | 19,386 | 4,908 | 3,097 | 0 |
| 30 Sep 16 | 18,821 | 4,622 | 2,971 | 0 |
| 30 Jun 16 | 18,072 | 4,350 | 2,886 | 0 |
| 31 Mar 16 | 17,340 | 4,156 | 2,773 | 0 |
| 31 Dec 15 | 16,809 | 3,692 | 5,446 | 0 |
| 30 Sep 15 | 16,160 | 3,510 | 5,318 | 0 |
| 30 Jun 15 | 15,502 | 3,340 | 5,158 | 0 |
| 31 Mar 15 | 14,736 | 3,099 | 2,167 | 0 |
| 31 Mar 14 | 12,083 | 2,339 | 4,096 | 0 |
Quality Earnings: AJANTPHARM has high quality earnings.
Growing Profit Margin: AJANTPHARM's current net profit margins (19.5%) are higher than last year (16.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AJANTPHARM's earnings have grown by 10.6% per year over the past 5 years.
Accelerating Growth: AJANTPHARM's earnings growth over the past year (32.5%) exceeds its 5-year average (10.6% per year).
Earnings vs Industry: AJANTPHARM earnings growth over the past year (32.5%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: AJANTPHARM's Return on Equity (23.8%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:14 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ajanta Pharma Limited is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Rashmi Sancheti Shetty | Anand Rathi Shares and Stock Brokers Limited |
| null null | Asian Markets Securities Private Limited |